You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 27, 2026

List of Excipients in Branded Drug GREEN GUARD FIRST AID EYE WASH


✉ Email this page to a colleague

« Back to Dashboard


Excipient Strategy and Commercial Opportunities for Green Guard First Aid Eye Wash

Last updated: March 3, 2026

What is the Excipient Composition of Green Guard First Aid Eye Wash?

Green Guard First Aid Eye Wash typically comprises sterile, isotonic aqueous solutions with additional excipients designed for eye safety, stability, and preservation. Common excipients include:

  • Buffering agents: Boric acid or sodium borate to maintain pH around 7.0.
  • Preservatives: Benzalkonium chloride or phenylmercuric nitrate (though preservative-free formulations are increasingly favored).
  • Humectants: Glycerin or polyethylene glycol (PEG) for maintaining solution stability.
  • Stabilizers: EDTA to chelate metal ions and prevent microbial growth.
  • Salts: Sodium chloride to match osmolarity (~290 mOsm/kg).

Table 1 compares typical excipients:

Excipients Purpose Typical Concentration
Boric acid pH buffering 0.25–0.75%
Sodium borate Buffering 0.5–1%
Benzalkonium chloride Preservation 0.01%
Glycerin Moisturizing, stabilization 1–2%
EDTA Microbial control, chelation 0.01–0.05%
Sodium chloride Osmotic adjustment 0.9%

What Are the Commercial Opportunities with Excipient Selection?

Enhanced Product Stability and Shelf Life

Choosing preservative-free formulations or alternative preservatives can extend shelf life and appeal to patients with sensitivities. Using stabilizers improves microbiological stability without compromising safety.

Market Differentiation Through Formulation Advantages

  • Preservative-Free or Reduced-Preservative Formulations: Rising consumer preference for preservative-free products favors multi-dose bottles with advanced barriers or single-use formats.
  • pH Optimization: Fine-tuning pH around eye compatibility (7.0–7.4) improves tolerability and reduces discomfort.
  • Specialized Excipients: Incorporating lubricants or soothing agents like aloe vera or formulating with hypoallergenic excipients can differentiate products.

Regulatory and Patent Considerations

Formulation patents based on excipient combinations or novel stabilizer systems can provide competitive protection.

Cost Efficiency in Manufacturing

Choosing excipients that are readily available, cost-effective, and compatible with existing manufacturing infrastructure reduces production costs. For example, glycerin and sodium chloride are cheap and stable.

Expansion into Adjacent Markets

Development of eye wash solutions with enhanced formulations supports entry into:

  • Retail consumer markets
  • Hospital and clinic supplies
  • Industrial safety sectors

Trends Driving Opportunities

  • Clean label formulations: Avoiding preservatives like benzalkonium chloride.
  • Sustainability: Developing biodegradable packaging compatible with formulations.
  • Personalized formulations: Tailoring excipients for specific age groups or sensitivities.

What Challenges Impact Excipient Strategy?

  • Regulatory restrictions: Limitations on certain preservatives in multi-dose eye washes.
  • Safety profiles: Ensuring excipients do not cause irritations or allergies.
  • Manufacturing complexity: Balancing stability and comfort with simplicity.

What are the Regulatory Considerations?

  • Compliance with FDA (21 CFR Part 310), EMA, and other global standards.
  • Claims related to preservative-free formulations require validation.
  • Documentation of excipient safety, particularly in sensitive populations (children, elderly).

What Are the Key Patent Cases?

Patent protection often covers:

  1. Specific excipient combinations that improve stability.
  2. Novel preservative systems reducing irritancy.
  3. Unique pH-buffering systems for enhanced tolerability.

Business Opportunities Summary

  • Developing preservative-free or reduced-preservative eye wash solutions addresses consumer preferences and regulatory trends.
  • Formulation innovations with stabilizers and buffering agents extend shelf life and improve product safety.
  • Cost-effective excipient choices optimize margins and facilitate large-scale manufacturing.
  • Patent filings based on unique excipient combinations provide competitive barriers.

Key Takeaways

  1. Excipient choice in Green Guard First Aid Eye Wash influences stability, safety, shelf life, and user experience.
  2. Market trends favor preservative-free and hypoallergenic formulations.
  3. Cost-efficient excipients like glycerin, sodium chloride, and stabilizers support scalability.
  4. Patents related to excipient systems can secure competitive advantage.
  5. Regulatory compliance remains a key consideration in excipient selection and formulation development.

FAQs

1. How does excipient choice impact eye wash safety?
Excipients affect the solution’s pH, osmolarity, and preservative content, influencing ocular irritation. Choosing biocompatible, non-irritating excipients enhances safety.

2. What are the main market drivers for excipient innovation in eye washes?
Consumer demand for preservative-free products, regulatory shifts away from certain preservatives, and the desire for longer shelf life drive innovation.

3. Which excipients are most commonly avoided in eye wash products?
Certain preservatives like thiomersal are rarely used due to toxicity concerns. Preservative-free formulations use barrier systems instead.

4. Can alternative excipients extend the shelf life of eye wash solutions?
Yes; stabilizers like EDTA can prevent microbial growth, and advanced packaging can preserve integrity, extending shelf life.

5. What role do patent protections play in excipient selection?
Patents on novel excipient combinations or stabilization systems can defend market share and justify investments in formulation R&D.


References

[1] Food and Drug Administration (FDA). (2022). Over-the-Counter Ophthalmic Drugs. Retrieved from https://www.fda.gov/

[2] European Medicines Agency (EMA). (2021). Guidelines on Eye Preparations.
[3] Suganuma, K., & Kato, T. (2020). Excipient selection in ophthalmic formulations. International Journal of Pharmaceutics, 585, 119495.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.